Till Capital Ltd.

Till Capital Ltd. is not a good value stock. Till Capital Ltd. has good growth characteristics. Till Capital Ltd. is not very popular among insiders. Tradey thinks it is not wise to invest in Till Capital Ltd..
Log in to see more information.
Till Capital Ltd. operates as holding company, which engages in the reinsurance business. It also in...
TIL Fundamental Data by TradingView

News

Instil Bio price target raised by $7 at H.C. Wainwright, here's why
Instil Bio price target raised by $7 at H.C. Wainwright, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nTIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2024.\nThe post TIL Stock...\n more…

Instil Bio reports Q2 EPS ($2.29), two estimates ($2.98)
Instil Bio reports Q2 EPS ($2.29), two estimates ($2.98)

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Instil Bio reports Q2 adjusted EPS ($1.57) vs ($2.03) last year
Instil Bio reports Q2 adjusted EPS ($1.57) vs ($2.03) last year

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Globe Newswire In-licensed SYN-2510/IMM2510, a potentially best-in-class PD-L1xVEGF bispecific antibody, and SYN-27M/IMM27M, a next-generation ADCC-enhanced anti-CTLA-4 antibodyEntered into a 15-year lease for our...\n more…

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generat
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generat

Globe Newswire DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, Instil ) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, ImmuneOnco ), today announced...\n more…